Shareholder Derivative

Shareholders say in a federal derivative complaint that directors of Ophthotech Corp. overhyped the prospects of their experimental macular degeneration drug Fovista, whose failure whacked 86 percent off the share prices, erasing nearly $1.2 billion in market capitalization.

MANHATTAN — Shareholders say in a federal derivative complaint that directors of Ophthotech Corp. overhyped the prospects of their experimental macular degeneration drug Fovista, whose failure whacked 86 percent off the share prices, erasing nearly $1.2 billion in market capitalization.

Categories / Securities

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Shareholder Derivative

Subscribe to Closing Arguments

Additional Reads